VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 11,105 shares, a decline of 55.8% from the December 15th total of 25,097 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 27,543 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily trading volume, of 27,543 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.4% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

VivoSim Labs Price Performance

Shares of VivoSim Labs stock traded up $0.02 during trading hours on Friday, hitting $2.03. 10,991 shares of the company’s stock traded hands, compared to its average volume of 39,500. The stock has a market capitalization of $5.30 million, a price-to-earnings ratio of -0.46 and a beta of 1.18. VivoSim Labs has a 12-month low of $1.41 and a 12-month high of $21.96. The company has a fifty day simple moving average of $2.11 and a 200-day simple moving average of $2.33.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The business had revenue of $0.03 million during the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.